PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
10 hedge funds and large institutions have $11.6M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
150% more funds holding
Funds holding: 4 → 10 (+6)
23% more capital invested
Capital invested by funds: $9.43M → $11.6M (+$2.18M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Cannell & Co
New York
|
+$146K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$143K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$81.6K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$11.2K |
| 5 |
HI
Harbour Investments
Madison,
Wisconsin
|
+$5.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$25.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BI
1
BVF Inc
San Francisco,
California
| $7.59M | – | – | – |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $3.61M | – | – | – |
|
|
CC
3
Cannell & Co
New York
| $150K | +$146K | +2,600 | New |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $148K | +$143K | +2,557 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| $84K | +$81.6K | +1,457 | New |
|
|
ACM
6
ACT Capital Management
Wayne,
Pennsylvania
| $12K | – | – | – |
|
|
7
Group One Trading
Chicago,
Illinois
| $12K | +$11.2K | +200 | New |
|
|
HI
8
Harbour Investments
Madison,
Wisconsin
| $6K | +$5.6K | +100 | New |
|
|
9
Morgan Stanley
New York
| $2K | -$25.8K | -460 | -94% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $2K | +$1.68K | +30 | New |
|
PHXM Hedge Fund Activity: Q3 2021 in Review
10 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q3 2021, worth a combined $11.6M — up 23% from $9.43M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PHXM positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Cannell & Co, opening a new position worth an estimated $146K. The largest seller was Morgan Stanley, cutting an estimated $25.8K.
- 10 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q3 2021, up from 4 in Q2 2021.
- Funds reported $11.6M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q3 2021, up 23% quarter-over-quarter.
- 6 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q3 2021 and 0 closed out, a net change of +6 holders.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q3 2021 was Cannell & Co, an estimated $146K added.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q3 2021 was Morgan Stanley, an estimated $25.8K sold.
Based on aggregated 13F filings for Q3 2021.